SCHEMBL7179526

SCHEMBL7179526

COc1cc(C(=O)c2ccccc2)c(OC)c(OC)c1[PH](=O)C(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 6/20 0.41
LMNA P02545 5/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
RECQL P46063 1/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KMT2A Q03164 3/20 0.41
GFER P55789 1/20 0.41
ATM Q13315 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
TUBB4A P04350 3/20 0.38
TUBB P07437 3/20 0.38
TUBA3C P0DPH7 3/20 0.38
TUBA1B P68363 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188320 0.92 MAPT (0.42) TP53GAAMAPTLMNAKDM4E
SCHEMBL7190266 0.90 MAPT (0.39) TP53GAAMAPTLMNAKDM4E
SCHEMBL7189610 0.89 MAPT (0.40) TP53GAAMAPTLMNAKDM4E
SCHEMBL5043185 0.89 MAPT (0.45) TP53GAAMAPTLMNAKDM4E
SCHEMBL7180822 0.89 ATM (0.39) TP53GAAMAPTLMNAKDM4E
SCHEMBL7188996 0.87 MAPT (0.44) TP53GAAMAPTLMNAKDM4E
SCHEMBL7188161 0.86 MAPT (0.43) TP53GAAMAPTLMNAKDM4E
SCHEMBL7175301 0.85 TUBB4A (0.39) TP53GAAMAPTLMNAKDM4E
SCHEMBL7186768 0.84 MAPT (0.41) TP53GAAMAPTLMNAKDM4E
SCHEMBL7182523 0.83 MAPT (0.42) TP53GAAMAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TP53 3575/4885GAA 4753/4885MAPT 4870/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TP53 3524/4885GAA 4793/4885MAPT 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.